An Open-Label, One-Arm, One-Sequence Crossover Drug-Drug Interaction Study in Oncology Subjects to Evaluate the Potential Effect of Custirsen (OGX-011) on the Pharmacokinetics of Paclitaxel

Trial Profile

An Open-Label, One-Arm, One-Sequence Crossover Drug-Drug Interaction Study in Oncology Subjects to Evaluate the Potential Effect of Custirsen (OGX-011) on the Pharmacokinetics of Paclitaxel

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Aug 2017

At a glance

  • Drugs Custirsen (Primary) ; Carboplatin; Paclitaxel
  • Indications Solid tumours
  • Focus Pharmacokinetics
  • Sponsors OncoGenex Technologies
  • Most Recent Events

    • 01 Oct 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 28 Jun 2013 Planned end date changed from 1 Apr 2013 to 1 Oct 2013 as reported by ClinicalTrials.gov.
    • 24 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top